	US 12,365,705 B2
	Epitope tags recognized by specific binders
Steffen Frey, Gottingen (DE); Hansjoerg Goetzke, Hannover (DE); Davilla Luis Felipe Opazo, Goettingen (DE); Paal Erik Gustav Stenmark, Jaerfaella (SE); and Carranza Markel Martinez, Stockholm (SE)
Assigned to NANOTAG BIOTECHNOLOGIES GmbH, Goettingen (DE)
Appl. No. 17/274,755
Filed by NANOTAG BIOTECHNOLOGIES GmbH, Goettingen (DE)
PCT Filed Sep. 11, 2019, PCT No. PCT/EP2019/074153 § 371(c)(1), (2) Date Mar. 11, 2021, PCT Pub. No. WO2020/053239, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 18193663 (EP), filed on Sep. 11, 2018; and application No. 19160485 (EP), filed on Mar. 4, 2019.
Prior Publication US 2022/0048947 A1, Feb. 17, 2022
Int. Cl. A61K 38/00 (2006.01); C07K 7/08 (2006.01); C07K 14/435 (2006.01)

CPC C07K 7/08 (2013.01) [C07K 14/435 (2013.01); C07K 14/43595 (2013.01); C07K 2319/40 (2013.01)]

13 Claims

1. A single domain antibody that is capable of binding a peptide having the sequence SRLEEELRRRLTE (SEQ ID NO: 04), wherein the antibody comprises CDR1, CDR2, and CDR3 sequences selected from the group consisting of:

(a) a CDR1 sequence having the sequence of GVTISALNAMAMG (SEQ ID NO: 115), a CDR2 sequence having the sequence of AVSERGNAM (SEQ ID NO: 116), and a CDR3 sequence having the sequence of LEDRVDSFHDY (SEQ ID NO: 117); and

(b) a CDR1 sequence having the sequence of GVTISALNAMAMG (SEQ ID NO: 115), a CDR2 sequence having the sequence of AVSSRGNAM (SEQ ID NO: 119), and a CDR3 sequence having the sequence of LEDRVDSFHDY (SEQ ID NO: 117).